Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer - Trial NCT06347198
Access comprehensive clinical trial information for NCT06347198 through Pure Global AI's free database. This Phase 1 trial is sponsored by Wuhan Union Hospital, China and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Wuhan Union Hospital, China
Timeline & Enrollment
Phase 1
Apr 10, 2024
May 01, 2025
Primary Outcome
Intestinal microbiota diversity, abundance and taxonomic information,adverse events
Summary
This is a single-center exploratory clinical study to explore the efficacy and safety of Oral
 Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment
 in Metastatic Colorectal Cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06347198
Non-Device Trial